Absorb, which the company claims is the first drug eluting vascular scaffold, is made of a naturally dissolvable polylactide material, which gets restored as a normal blood vessel.
The treated vessel may expand and contract as needed to increase the flow of blood to the heart in response to normal activities such as exercising, according to the company.
The BVS also delivers an anti-proliferative drug, everolimus, that inhibits in-stent neointimal growth in the coronary vessels following stent implantation.
The international launch of Absorb is based on a robust clinical trial programme that includes five studies, conducted in more than 20 countries.
The study data demonstrated that Absorb performs similar to a drug eluting stent across measures including major adverse cardiovascular events and target lesion revascularisation.
Abbott medical devices executive vice president John M Capek said; "Abbott has remained committed to meeting the growing physician and patient demand for a bioresorbable vascular scaffold – from the initial device developed nearly 10 years ago to the expansion of our manufacturing capabilities to support this international launch."
Erasmus University Hospital, Rotterdam, interventional cardiology professor Dr Patrick W Serruys said; "With the launch of Absorb, a scaffold that disappears after doing its job is no longer a dream, but a reality."
The company said Absorb BVS, which is currently is in development, is neither approved nor authorised for sale in the US.